Tavapadon

• Product Name Alternative:

  AZD6140; AR-C 126532XX, Hydroxytolbutamide

• UNSPSC Description:

  Tavapadon (PF-06649751) is an orally active and highly selective dopamine D1/D5 receptor partial agonist. Tavapadon is effective in enabling movement and reducing disability and has the potential for Parkinson's disease[1].

• Target Antigen:

  Dopamine Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/tavapadon.html

• Purity:

  99.59

• Solubility:

  DMSO : 66.67 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C1NC(C(C)=C(C2=CC=C(OC3=NC=CC=C3C(F)(F)F)C=C2C)N1C)=O.[(-)].[Rotation]

• Molecular Weight:

  391.34

• References & Citations:

  [1]Young D, et al. D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited DyskinesiaSide Effects. ACS Chem Neurosci. 2020 Feb 19;11(4):560-566.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Phase 3

• CAS Number:

  1643489-24-0